Clinical Trials

Numerous clinical trials evaluate interventions across diverse therapeutic areas, including neuropsychiatric conditions (bipolar I disorder, major depressive disorder, migraine), metastatic colorectal cancer, bronchial asthma, and sarcopenia. Spanning Early Phase 1 through Phase 4, these studies encompass completed, actively recruiting, terminated, and withdrawn protocols. Research sponsors include pharmaceutical companies—such as AstraZeneca, Abbott, and Dr. Reddy's Laboratories—alongside academic and clinical institutions, including the National Cancer Institute, Naples and the Mario Negri Institute for Pharmacological Research.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT07017010 RECRUITING
Reading Difficulties
Ohio State University
 2025-09-12
NCT06714357 RECRUITING
Colorectal Cancer Metastatic
National Cancer Institute, Naples
 2025-03-12 PHASE2
NCT07572500 WITHDRAWN
Hypoxia; OSA; Obesity
Stanford University
 2025-11
NCT07023068 ENROLLING_BY_INVITATION
Lung Cancers
Peking Union Medical College Hospital
 2024-09-28 EARLY_PHASE1
NCT05757765 NOT_YET_RECRUITING
Sarcopenia
Zuyderland Medisch Centrum
 2023-02-27
NCT03689114 COMPLETED
Epilepsies, Partial
Mario Negri Institute for Pharmacological Research
 2021-05-10 PHASE4
NCT04088240 TERMINATED
Elevated Triglycerides; Cardiovascular Risk Factor
University of Arizona
 2019-09-04
NCT06533891 WITHDRAWN
Insulin Resistance
University of Arizona
 2020-02-01
NCT04796207 COMPLETED
Traumatic Brain Injury (TBI); Chronic Traumatic Encephalopathy (CTE)
University of Arizona
 2019-05-28
NCT03694314 COMPLETED
Disturbances in Initiating and Maintaining Sleep; Behavior Problem
University of Pennsylvania
 2018-05-15
NCT02446652 WITHDRAWN
Cervical Cancer
National Institute of Cancerología
 2015-01-01 PHASE3
NCT02893852 COMPLETED
Motor Skills Disorders; Attention Deficit and Disruptive Behavior Disorders
Federal University of Minas Gerais
 2016-05-12
NCT01898676 UNKNOWN
Epilepsy
Vince & Associates Clinical Research, Inc.
 2013-07 PHASE1
NCT01333631 UNKNOWN
Pancreatic Cancer
Soroka University Medical Center
 2011-06 PHASE2
NCT01750541 COMPLETED
Psychomotor Agitation
Shahid Beheshti University of Medical Sciences
 2012-12 PHASE3
NCT00581009 COMPLETED
Major Depressive Disorder; Bipolar Disorder
University of California, Irvine
 2001-05-30 PHASE1; PHASE2
NCT01132183 COMPLETED
Healthy
Dr. Reddy's Laboratories Limited
 2007-02 PHASE1
NCT01055938 COMPLETED
Healthy
Dr. Reddy's Laboratories Limited
 2006-12 PHASE1
NCT01056627 COMPLETED
Healthy
Dr. Reddy's Laboratories Limited
 2006-12 PHASE1
NCT00312455 COMPLETED
Substance-related Disorders
National Institute on Drug Abuse (NIDA)
 2004-07 PHASE2
NCT00107731 COMPLETED
Bipolar I Disorder
AstraZeneca
 2004-04 PHASE3
NCT00114686 COMPLETED
Bipolar I Disorder; Alcohol Dependence
AstraZeneca
 2006-01 PHASE3
NCT00153270 COMPLETED
Bronchial Asthma
Centre of Chinese Medicine, Georgia
 2000-09 PHASE4
NCT00195741 COMPLETED
Migraine
Abbott
 2003-05 PHASE3
NCT00081380 COMPLETED
Bipolar Disorder
AstraZeneca
 2004-03 PHASE3
NCT00000629 COMPLETED
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID)
 PHASE1
NCT00309686 COMPLETED
Affective Psychosis, Bipolar; Bipolar Disorder; Mania
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
 2006-04 PHASE3

(data from https://clinicaltrials.gov, updated on 2025-12-08)

Check the MOCAc-PLGL(Dpa)AR product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

MOCAc-PLGL(Dpa)AR acts as a selective fluorogenic substrate that binds the active sites of matrix metalloproteinases, including MMP-2, MMP-7, and MMP-9, leading to endopeptidase-catalyzed cleavage at the Gly-Leu peptide bond and physical separation of the MOCAc fluorophore from the Dpa quencher. This cleavage relieves intramolecular fluorescence resonance energy transfer quenching to generate a greater than ten-fold increase in fluorescence intensity, enabling precise quantification of extracellular matrix remodeling and proteolytic activity associated with disease progression in indications such as metastatic colorectal cancer.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.